A new comparative analysis examines retifanlimab against avelumab in metastatic Merkel cell carcinoma, giving clinicians their first structured side-by-side view of two checkpoint inhibitor options in this rare, aggressive skin cancer. DocWireNews flagged the analysis, and it lands at a moment when treatment sequencing in metastatic MCC has no settled playbook.

Merkel cell carcinoma is uncommon enough that no large randomized head-to-head trial has ever directly compared the PD-1 agent retifanlimab with the PD-L1 agent avelumab. That absence shapes everything. Clinicians have been choosing between them on the basis of separate single-arm trials, different patient populations, and indirect comparisons of response rates and survival curves. A formal comparative analysis, even a retrospective or indirect one, gives the field something firmer to argue from.

What does the comparison actually change for practice?

The honest answer: it sharpens the conversation, not the guideline. Avelumab built its case in metastatic MCC as maintenance therapy after chemotherapy, then as first-line treatment in the JAVELIN Merkel 200 program. Retifanlimab arrived later, securing approval on the strength of the PODIUM-201 trial in patients with recurrent or metastatic disease. Two different trial designs, two different starting points, and no shared control arm.

A comparative analysis helps by putting the datasets side by side — patient characteristics, response patterns, durability signals, tolerability — so oncologists and dermatologists co-managing these patients can see where the profiles converge and where they diverge. For referring dermatologists, the practical relevance is concrete: MCC often presents in sun-damaged skin of older, immunocompromised patients, and the choice of first-line systemic therapy affects counseling, monitoring schedules, and coordination with medical oncology.

Why indirect comparisons carry weight here

In ultra-rare tumors, indirect treatment comparison is frequently the best available evidence. Analysts typically match cohorts on age, performance status, prior therapy, and disease burden, then compare outcomes statistically. The method has real limits. Confounding by indication, era effects, and differing response criteria can all distort the picture.

Still, practitioners make these decisions weekly without any comparative scaffolding at all. Any structured analysis, with its limitations stated plainly, beats anecdote.

The context clinicians should hold onto

Checkpoint inhibition transformed metastatic MCC from a chemotherapy-only disease with dismal outcomes into one where durable responses occur in a meaningful fraction of patients. Both retifanlimab and avelumab sit inside that shift. What remains unresolved — and what analyses like this one chip away at — is whether drug class, timing, or patient selection moves the needle on who gets those durable responses.

For Derm Field readers in general dermatology, the takeaway is a referral-adjacent one: when a biopsy-confirmed MCC goes systemic, the systemic conversation now includes two immune-oncology pathways with a growing comparative literature. Asking the treating oncologist which agent, and why, is a fair question with an increasingly evidence-based answer.

Full methodological details, cohort sizes, and outcome figures from the analysis should be read in the primary presentation before any practice change. As comparative and real-world data in metastatic MCC accumulate, expect treatment sequencing debates — immune therapy first versus after chemotherapy, PD-1 versus PD-L1 — to move from conference hallways into formal guidance.